New York State Common Retirement Fund Decreases Position in Celgene Co. (CELG)

New York State Common Retirement Fund trimmed its holdings in shares of Celgene Co. (NASDAQ:CELG) by 15.5% in the first quarter, HoldingsChannel.com reports. The firm owned 1,609,500 shares of the biopharmaceutical company’s stock after selling 296,009 shares during the period. New York State Common Retirement Fund’s holdings in Celgene were worth $151,840,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Bruderman Asset Management LLC bought a new position in shares of Celgene during the fourth quarter worth about $25,000. Murphy Pohlad Asset Management LLC bought a new position in shares of Celgene during the fourth quarter worth about $25,000. Athena Capital Advisors LLC bought a new position in shares of Celgene during the fourth quarter worth about $27,000. Investors Research Corp bought a new position in shares of Celgene during the first quarter worth about $28,000. Finally, Liberty Wealth Management LLC bought a new position in shares of Celgene during the fourth quarter worth about $29,000. 75.21% of the stock is owned by hedge funds and other institutional investors.

CELG opened at $95.24 on Monday. The stock has a market cap of $67.17 billion, a P/E ratio of 12.52, a price-to-earnings-growth ratio of 0.44 and a beta of 1.68. Celgene Co. has a fifty-two week low of $58.59 and a fifty-two week high of $97.07. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 2.42.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.45 by $0.10. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The company had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.01 billion. During the same quarter last year, the business earned $2.05 earnings per share. Celgene’s revenue was up 13.8% compared to the same quarter last year. Sell-side analysts predict that Celgene Co. will post 9.85 earnings per share for the current fiscal year.

Several equities analysts have recently commented on CELG shares. Jefferies Financial Group cut shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 price target on the stock. in a research report on Friday, February 1st. BidaskClub raised shares of Celgene from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. William Blair reaffirmed a “buy” rating on shares of Celgene in a research report on Thursday, February 28th. Cantor Fitzgerald cut shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 price target on the stock. in a research report on Friday, April 5th. Finally, Cowen started coverage on shares of Celgene in a research report on Tuesday, February 26th. They set a “market perform” rating and a $102.00 price target on the stock. Eighteen equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $95.56.

TRADEMARK VIOLATION NOTICE: “New York State Common Retirement Fund Decreases Position in Celgene Co. (CELG)” was originally published by WKRB News and is owned by of WKRB News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.wkrb13.com/2019/05/27/new-york-state-common-retirement-fund-decreases-position-in-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: Dow Jones Industrial Average (DJIA)

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.